

Message

From: Dass, Brinda [Brinda.Dass@fda.hhs.gov]
Sent: 7/30/2016 1:43:40 PM
To: Wozniak, Chris [wozniak.chris@epa.gov]; Kough, John [Kough.John@epa.gov]; McAllister, Janet C (CDC) [jvm6@cdc.gov]; Mutebi, John-Paul (CDC) [grv0@cdc.gov]
CC: Epstein, Laura [Laura.Epstein@fda.hhs.gov]; Evdokimov, Evgenij A [Evgenij.Evdokimov@fda.hhs.gov]
Subject: OCC edits Working copy EA 073016.docx
Attachments: OCC edits Working copy EA 073016.docx

Hi Chris, John, Janet, and John Paul:

Please find attached our close to final version of the Oxitec EA where we have made a few edits in response to both your comments as well as those from our Chief Counsel's office. We have left your comment bubbles in the document and provided our responses to each of them for you to see where we have edited in response to your suggestions. Please let us know if you find our responses and edits suitable or if you have further comments/suggestions for us. There are still a few comments pending that we are working on with FDA OCC and hope to resolve by Monday or Tuesday of next week at which point we hope to move to making the document 508 compliant and ready to post. Once you have looked at the document and let us know you are ok with it we will remove your comment bubbles as well to finalize the document. If at all possible given your busy schedules it would be great to hear back from all of you by Tuesday of next week.

Many thanks
Best

Brinda